Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Friday programming ahead of the official kickoff of the 2021 ASCRS Annual Meeting featured three Subspecialty Day programs on refractive, glaucoma, and cornea.
➤ Combination pharmaceutical therapy being investigated for presbyopia meets study endpoints ➤ Positive results in Phase 2 clinical trial for IOP-lowering agent ➤ Phase 3 results from study of gene therapy for retinal neurodegenerative diseases ➤ Positive safety results in Phase 1 anti-VEGF treatment ➤ ASCRS news and events
When a patient comes in prior to cataract surgery, it’s important to do a careful evaluation to see what conditions they might have and how this could impact IOL selection. Two physicians discussed conditions to be aware of when considering presbyopia-correcting IOLs and how to talk to patients prior to surgery.
Enhanced monofocal and “ringless” EDOFs are a couple of the names floating around for a newer type of IOL designed to extend depth of focus while maintaining, as much as possible, the quality of distance vision provided by a monofocal IOL. This article explores physician experience with these new IOL options.
➤ Positive topline results in Phase 3 study for temporary presbyopia therapy ➤ Study: New therapy for ocular infections ➤ Analysis of more than half a million cataract surgeries yields PCO insights ➤ Patients blinded from AMD benefit from visual prosthetic ➤ New company focuses on refractive pharmaceutical treatments ➤ ASCRS events
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ Positive topline results for Phase 3 trial of drug for allergic conjunctivitis ➤ Phase 2 trial of progesterone topical gel for DED begins ➤ Breakthrough Device Designation granted to remote glaucoma management system ➤ Glaukos enters into licensing agreement for presbyopia treatment ➤ Increase in laser vision correction procedures continues ➤ Guide on climate change and eye health ➤ ASCRS events
➤ FDA accepts IND for presbyopia-correcting eye drop ➤ Pivotal study of new tech against gold standard patching treatment of amblyopia ➤ Topline results from trial to reverse pharmacologically induced mydriasis ➤ Pivotal study of fixed-combination tropicamide/phenylephrine product for mydriasis ➤ ASCRS introduces new Richard L. Lindstrom Lecture
➤ FDA accepts NDA for fixed-combination mydriatic agent ➤ NDA accepted by FDA for dry eye nasal spray ➤ NDA submitted for drop to treat presbyopia ➤ Study to assess outcomes of ab interno canaloplasty ➤ Largest study of glaucoma genetics published ➤ Iridex and Topcon enter into strategic agreement ➤ COVID-19 vaccine update ➤ ASCRS Journal Club on March 11
➤ PMA submitted to FDA for small-aperture IOL ➤ Preclinical results for new class of non-prostaglandin analogs for IOP lowering ➤ A Phase 2 clinical trial begins enrollment for topical presbyopia-correcting drop ➤ Home OCT technology used in clinical trial to reduce participant visits to offices ➤ ASCRS Journal Club on March 11